Bruno Tse currently serves as the Vice President of Business Development for PepTech Corporation, heading the business development efforts and corporate strategies of PepTech. Prior to this position, Bruno had played important roles in business development at several start-ups, including Amicus Therapeutics and Orphagen Pharmaceuticals. Bruno had also served as a Research Fellow at Merck where he completed a total synthesis of (-)-galbonolide B, a natural antifungal agent, by himself. He is a co-inventor of over ten issued patents, covering the discoveries of novel therapeutics in infectious diseases and cholesterol regulation. He earned his Ph.D. in chemistry at Harvard where he was awarded Robert Burns Woodward Prize, and holds an M.B.A. from the Wharton School of Business. He is also a registered patent agent and a four-time ironman triathlete.
More and more pharmaceutical companies are outsourcing their R&D work to China. In this presentation, Bruno will discuss the current trends of China’s fast-growing CRO industry. Using PepTech Corporation as a case study, Bruno will further discuss the keys to success for a chemistry service company.
